Related Experiment Videos
New drug development in non-Hodgkin lymphomas
1National Cancer Institute, Executive Plaza North, Room 741, Bethesda, MD 20892, USA. chesonb@ctep.nci.nih.gov
Current Oncology Reports
|April 11, 2001
Summary
Non-Hodgkin lymphomas (NHL) initially respond to chemotherapy but often progress. New targeted therapies and clinical studies are crucial for improving cure rates in NHL patients.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Non-Hodgkin lymphomas (NHL) frequently exhibit initial sensitivity to chemotherapy.
- Despite initial responses, most patients with NHL experience disease progression and mortality.
- Current therapeutic strategies for NHL face limitations due to disease recurrence.
Purpose of the Study:
- To review emerging therapeutic agents for non-Hodgkin lymphomas (NHL).
- To discuss novel mechanisms of action in NHL drug development.
- To highlight the importance of personalized medicine and clinical trials in advancing NHL treatment.
Main Methods:
- Review of current clinical development landscape for NHL therapies.
- Analysis of novel drug classes targeting specific molecular pathways.
- Discussion of personalized medicine approaches based on tumor and patient heterogeneity.
Main Results:
- Several new agents targeting apoptosis, cell cycling, angiogenesis, Ras gene farnesylation, histone deacetylase, and proteasome inhibition are in development.
- Emerging therapies offer unique mechanisms of action beyond conventional chemotherapy.
- Individualized treatment strategies based on specific genetic and immunologic targets are anticipated.
Conclusions:
- Advancements in understanding NHL biology are paving the way for targeted therapies.
- Personalized therapeutic strategies hold promise for overcoming treatment resistance in NHL.
- Accelerated enrollment in high-quality clinical studies is essential for delivering novel agents and improving NHL cure rates.